{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:48:05Z","timestamp":1776923285064,"version":"3.51.2"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":1013,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1002\/rth2.12319","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T05:48:57Z","timestamp":1583732937000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention\/stenting"],"prefix":"10.1016","volume":"4","author":[{"given":"Monika","family":"Kozie\u0142","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana S.","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1002\/rth2.12319_bb0010","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision\u2010making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1002\/rth2.12319_bb0015","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","article-title":"Atrial fibrillation, stroke risk, and warfarin therapy revisited","volume":"44","author":"Bjorck","year":"2013","journal-title":"Stroke"},{"issue":"3","key":"10.1002\/rth2.12319_bb0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP\u2010AF) Pilot General Registry","volume":"16","author":"Lip","year":"2013","journal-title":"Europace"},{"issue":"30","key":"10.1002\/rth2.12319_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17300","article-title":"Combined anticoagulation and antiplatelet therapy for high\u2010risk patients with atrial fibrillation: a systematic review","volume":"17","author":"Lane","year":"2013","journal-title":"Health Technol Assess"},{"issue":"9","key":"10.1002\/rth2.12319_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first\u2010time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1002\/rth2.12319_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000382","article-title":"New\u2010onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long\u2010term follow\u2010up: a nationwide study","volume":"3","author":"Bang","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1002\/rth2.12319_bb0040","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1160\/TH16-12-0963","article-title":"Antithrombotic therapy for acute coronary syndrome: past, present and future","volume":"117","author":"Sibbing","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9526","key":"10.1002\/rth2.12319_bb0045","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/rth2.12319_bb0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"issue":"6","key":"10.1002\/rth2.12319_bb0055","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/rth2.12319_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1002\/rth2.12319_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One\u2010year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"issue":"9872","key":"10.1002\/rth2.12319_bb0070","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open\u2010label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/rth2.12319_bb0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long\u2010term anticoagulation therapy (RE\u2010LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1002\/rth2.12319_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial","volume":"179","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"issue":"4","key":"10.1002\/rth2.12319_bb0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1002\/rth2.12319_bb0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF\u2010TIMI48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"10.1002\/rth2.12319_bb0095","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jacc.2018.07.054","article-title":"Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease","volume":"72","author":"Sindet\u2010Pedersen","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1002\/rth2.12319_bb0100","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"issue":"16","key":"10.1002\/rth2.12319_bb0105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12319_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"issue":"10206","key":"10.1002\/rth2.12319_bb0115","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban\u2010based versus vitamin K antagonist\u2010based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST\u2010AF PCI): a randomised, open\u2010label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"10.1002\/rth2.12319_bb0120","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1002\/rth2.12319_bb0125","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/rth2.12319_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta\u2010analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1002\/rth2.12319_bb0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","article-title":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta\u2010analysis of pooled data from PIONEER\u2010AF PCI, RE\u2010DUAL PCI, and AUGUSTUS trials","volume":"22","author":"Potpara","year":"2019","journal-title":"Europace"},{"issue":"11","key":"10.1002\/rth2.12319_bb0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1002\/rth2.12319_bb0145","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1002\/rth2.12319_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1002\/rth2.12319_bb0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1002\/rth2.12319_bb0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1002\/rth2.12319_bb0165","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1002\/rth2.12319_bb0170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1002\/rth2.12319_bb0175","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non\u2010valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1002\/rth2.12319_bb0180","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow\u2010up and delta HAS\u2010BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12319_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2009.03.044","article-title":"Combining antiplatelet and anticoagulant therapies","volume":"54","author":"Holmes","year":"2009","journal-title":"J Am College Cardiol"},{"issue":"18","key":"10.1002\/rth2.12319_bb0190","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","article-title":"Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents","volume":"121","author":"Paikin","year":"2010","journal-title":"Circulation"},{"issue":"9706","key":"10.1002\/rth2.12319_bb0195","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/rth2.12319_bb0200","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/rth2.12319_bb0205","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"\"Triple therapy\" rather than \"triple threat\": a meta\u2010analysis of the two antithrombotic regimens after stent implantation in patients receiving long\u2010term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"issue":"12","key":"10.1002\/rth2.12319_bb0210","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2007.02.027","article-title":"Impact of major bleeding on 30\u2010day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial","volume":"49","author":"Manoukian","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1002\/rth2.12319_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001645","article-title":"Access and non\u2010access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta\u2010analysis","volume":"8","author":"Kwok","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"10.1002\/rth2.12319_bb0220","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1\u2010year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1002\/rth2.12319_bb0225","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","article-title":"Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention","volume":"4","author":"Verheugt","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"10.1002\/rth2.12319_bb0230","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/rth2.12319_bb0235","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1503\/cmaj.121218","article-title":"Rates of hemorrhage during warfarin therapy for atrial fibrillation","volume":"185","author":"Gomes","year":"2013","journal-title":"CMAJ"},{"issue":"10","key":"10.1002\/rth2.12319_bb0240","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/17474086.2019.1647779","article-title":"Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding","volume":"12","author":"Koziel","year":"2019","journal-title":"Exp Rev Hematol"},{"issue":"23","key":"10.1002\/rth2.12319_bb0245","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS\u2010BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2\u2010VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Roldan","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1002\/rth2.12319_bb0250","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. A North American perspective\u20102016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"10.1002\/rth2.12319_bb0255","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","article-title":"Long\u2010term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy","volume":"102","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1002\/rth2.12319_bb0260","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/europace\/euy054","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non\u2010vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","volume":"20","author":"Steffel","year":"2018","journal-title":"Europace"},{"issue":"20","key":"10.1002\/rth2.12319_bb0265","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug\u2010eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am College Cardiol"},{"issue":"1","key":"10.1002\/rth2.12319_bb0270","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1002\/rth2.12319_bb0275","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/rth2.12250","article-title":"Atrial fibrillation in patients with end\u2010stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation","volume":"3","author":"Konigsbrugge","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"10.1002\/rth2.12319_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022690","article-title":"Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA\u2010AFNET 8 study","volume":"8","author":"Reinecke","year":"2018","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/rth2.12319_bb0285","first-page":"737","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta\u2010analysis","volume":"33","author":"Harel","year":"2017","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1002\/rth2.12319_bb0290","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1160\/TH16-10-0807","article-title":"New developments in anticoagulants: past, present and future","volume":"117","author":"Weitz","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1002\/rth2.12319_bb0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13543784.2018.1416090","article-title":"New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds","volume":"27","author":"Dimitropoulos","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1002\/rth2.12319_bb0300","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 scientific sessions Sol Sherry distinguished lecture in thrombosis: factor XI as a target for new anticoagulants","volume":"38","author":"Weitz","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1002\/rth2.12319_bb0305","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12319_bb0310","first-page":"30","article-title":"Using machine learning for predicting length of hospital stay after stroke diagnosis, survival, stroke type and post\u2010stroke depression","author":"Osman","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12319_bb0315","first-page":"733","article-title":"A retrospective analysis of the real\u2010world use of idarucizumab at two tertiary centres in Toronto, Canada","author":"Abdulrehman","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"10.1002\/rth2.12319_bb0320","first-page":"4","article-title":"The impact of an educational intervention in patients with atrial fibrillation treated with warfarin: protocol of a clinical trial","volume":"3","author":"Costa","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"10.1002\/rth2.12319_bb0325","first-page":"16","article-title":"Design of the FRAIL\u2010AF trial: safety of switching from VKA to DOAC in frail elderly with atrial fibrillation","volume":"3","author":"Joosten","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"10.1002\/rth2.12319_bb0330","first-page":"131","article-title":"Effect of dabigatran in the very elderly on thrombinography and fibrinography parameters as assessed with the thrombodynamics System","volume":"3","author":"Foulon","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"10.1002\/rth2.12319_bb0335","first-page":"153","article-title":"Coagulation function tests to measure direct oral anticoagulant (DOAC) levels: comparison of routine and DOAC\u2010specific tests in the PAUSE study","volume":"3","author":"Douketis","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"S1","key":"10.1002\/rth2.12319_bb0340","first-page":"15","volume":"3","author":"Konigsbruegge","year":"2019","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922019926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922019926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:19:07Z","timestamp":1762863547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922019926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2475037922019926"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12319","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention\/stenting","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}